StockWatch
·

Fine Organic Industries Ltd Q2 FY27 Results

FINEORGQ2 FY27 Results
Filing
Result:Good· Market: Down#Margin expansion#Base effect#Record quarter
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue729.395.1%22.1%
Total Income760.035.8%22.9%
Expenditure561.005.3%18.0%
PBT199.037.3%39.1%
Net Profit152.1210.1%40.1%
OPM25.35%0.00pp2.72pp
NPM20.01%0.78pp2.46pp
EPS49.6210.1%40.2%
View full financials

Revenue +22% and PAT +40% YoY with margin expansion (OPM 25.4%, NPM 20.0%) are strong for chemicals, but a soft Q2FY26 comp base and the Thailand/Oleofine subsidiary consolidation (only half the quarter) inflate the headline growth beyond pure core/organic performance, capping it below a clean standout.

Q2 FY-2027 RESULTS · FINEORG

Fine Organic Q2 FY27: Consolidated PAT up 40% YoY on 22% revenue growth, margins expand

PAT +40.15% YoY · revenue +22.12% · margins expanding

02 Nov 2026 · 3 min read
Revenue

₹729.39 Cr

+22.12% YoY

PAT (consolidated)

₹152.12 Cr

+40.15% YoY

Net margin

20.01%

+2.5pp YoY

EPS

₹49.62

Fine Organic's consolidated revenue rose 22.1% YoY to ₹729.39 Cr (₹597.29 Cr in Q2 FY26) and 5.1% QoQ (₹694.17 Cr in Q1 FY27), with consolidated PAT up 40.1% YoY to ₹152.12 Cr (₹108.55 Cr) and 10.1% QoQ (₹138.14 Cr). Standalone PAT of ₹135.14 Cr grew 41.7% YoY but was flat QoQ (₹135.50 Cr in Q1 FY27), indicating the sequential consolidated gain was driven largely outside the parent entity. No exceptional items hit either statement this quarter, so the YoY jump is on a clean base — though it is also a soft comparison base: Q2 FY26 PAT itself had fallen ~7.6% YoY at the time, per prior press coverage, so part of this quarter's YoY strength reflects an easy comp rather than pure acceleration.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹729.39 Cr+5.1%+22.1%
Expenses₹561 Cr+5.3%+18%
PAT₹152.12 Cr+10.12%+40.15%
Net margin20.01%+0.8pp+2.5pp
EPS₹49.62+10.1%+40.2%

Consolidated net margin (PAT/total income) expanded to ~20.0% from 19.2% in Q1 FY27 and 17.6% a year ago, and operating profitability (total income less total expenses, ~26.2% of total income) also improved from both comparison quarters, consistent with the price-led realizations management flagged. No specific Q2 FY27 brokerage estimate could be located; the only comparable data point found was a full-year FY27 consensus revenue growth estimate of roughly 13% YoY, well below the 22% YoY printed this quarter, so vsStreet is left unknown rather than inferred. Against management's own prior guidance of "flat revenue growth" for FY27 (price-led, with capacities at full utilization and volume growth only from H2 FY28 post the SEZ and US plant commissioning), this print is well ahead — though part of that gap is inorganic: Fine Organic Industries (Thailand), previously an associate/JV, became a subsidiary with effect from September 9, 2026 after the Oleofine Organics (Sdn. Bhd.) acquisition lifted the group's indirect stake to 53%, and both entities are now consolidated line-by-line for only the back half of the quarter.

₹
4,719.424,970.215,2215,471.795,722.585,24207-3008-2109-1510-0811-02Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹5,242, up 2.1% over the past month of trading.

₹ Cr
056.79113.58170.37117.1Q1 FY26rev ₹588 Cr108.55Q2 FY26rev ₹597 Cr73.93Q3 FY26rev ₹555 Cr117.49Q4 FY26rev ₹625 Cr138.14Q1 FY27rev ₹694 Cr152.12Q2 FY27rev ₹729 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

What management guided (4 FY-2026 call)
Management anticipates flat revenue growth for FY27 and FY28 due to existing capacities operating at full utilization, with any top-line increase primarily driven by price rather than volume. Growth is expected to resume post-commissioning of the SEZ plant in India (expected H2 FY28) and the U.S. plant. Sustainable EBI

— This quarter: beat

Corporate activity this quarter lines up with the stated capex and expansion plans: the Oleofine stake was acquired for ~₹80 Cr, the company invested ₹55 Cr into its wholly-owned SEZ subsidiary on September 16, and the Board, at the same November 2 meeting that approved these results, raised the SEZ subsidiary's investment limit by a further ₹120 Cr (to ₹420 Cr) to fund the upcoming manufacturing unit management has guided will begin contributing to growth in H2 FY28. No management press release accompanied this filing, so there is no fresh management commentary to cross-check against the numbers beyond the audited notes and board outcome letter. Separately, a GST inspection was initiated in Maharashtra on October 30, 2026 — after the quarter closed — with no quantified exposure disclosed yet.

  • W1

    GST inspection in Maharashtra (initiated Oct 30, 2026) — watch for any quantified demand/penalty in upcoming disclosures

  • W2

    Q3 FY27 will carry a full quarter of Oleofine and Fine Organic Industries (Thailand) consolidation (vs ~3 weeks this quarter) — a cleaner read on their contribution to group revenue and margin

  • W3

    SEZ plant and U.S. plant progress toward management's guided H2 FY28 commissioning, against the ₹420 Cr investment limit now approved for the SEZ subsidiary

No exceptional items this quarter (unlike ₹6.98 Cr insurance settlement in Q1 FY26); consolidated PAT of ₹152.12 Cr includes an NCI loss of ₹0.11 Cr (equity holders' share ₹152.23 Cr) following the Oleofine (80%) and Fine Organic Industries (Thailand) stake moves effective Sept 9, 2026, which are consolidated line-by-line for only ~3 weeks of the quarter, slightly denting like-for-like comparability; pages and figures clearly legible.

Informational and educational content only. Not investment advice.